“We believe IHH has sufficient financial strength to tide it through the difficult times, as it also works to defer its non-critical expansion plans and further pare down its non-lira debt exposure,” says CGS-CIMB analyst Ngoh Yi Sin.
Follow us on Facebook and join our Telegram channel for the latest updates.
SINGAPORE (June 30): CGS-CIMB analyst Ngoh Yi Sin is maintaining “buy” on IHH Healthcare with a target price of RM6.25 ($2.03), which is based on an unchanged sum-of-the-parts (SOTP) valuation.
The rating comes after the release of IHH Healthcare’s 1Q20 results on Monday. The private healthcare operator posted a loss of RM319.8 million.
Never miss out on important financial news and get daily updates today
×
Download The Edge Singapore App
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
